BMY
Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 72.17$. Average daily volumn in 3 months 9.64M. Market cap 150.98B
Stock symbol : BMY. Exchange : NYSE. Currency : USD Lastest price : 70.71$. Total volume : 8.19M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Bristol-Myers Squibb Company (BMY)
Last Price
70.71$Change
-0.58Volume
8.19M
| Previous Close | 71.29 |
| Open | 71.03 |
| Day Range | 70.13-71.37 |
| Bid | 70.72 x 1k |
| Ask | 71.49 x 900 |
| Volume | 8.19M |
| Average Volume | 9.64M |
| Market Cap | 150.98B |
| Beta | 0.42 |
| 52 Week Range | 53.22-80.59 |
| Trailing P/E | 23.49 |
| Foward P/E | 8.83 |
| Dividend (Yield %) | 3.03% |
| Ex-Dividend Date | 2022-10-06 |
Financial Details
Organization
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi... cations; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Market Cap:
150.98BRevenue:
46.38BTotal Assets:
109.31BTotal Cash:
13.98B
News about "Bristol-Myers Squibb Company"
With 78% ownership of the shares, Bristol-Myers Squibb Company (NYSE:BMY) is heavily dominated by institutional owners
Source from : YAHOO!Finance - 12 hours ago
If you want to know who really controls Bristol-Myers Squibb Company ( NYSE:BMY ), then you'll have to look at ...See details»
What Bristol-Myers Squibb Company's (NYSE:BMY) ROE Can Tell Us
Source from : Nasdaq - 3 days ago
We'll use ROE to examine Bristol-Myers Squibb Company (NYSE:BMY), by way of a worked example. Return on equity or ROE is a key measure used to assess how efficiently a company's management is ...See details»
Bristol Myers Squibb (BMY) Stock Moves -0.81%: What You Should Know
Source from : YAHOO!Finance - 1 days ago
Bristol Myers Squibb (BMY) closed the most recent trading day at $70.71, moving -0.81% from the previous trading session.See details»
Giovanni Caforio Sells 25,000 Shares of Bristol-Myers Squibb (NYSE:BMY) Stock
Source from : Defense World - 15 hours ago
CEO Giovanni Caforio sold 25,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $69.71, for a total value of $1,742,750.00.See details»
Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Increased by Allworth Financial LP
Source from : Defense World - 1 days ago
Allworth Financial LP lifted its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 15.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange ...See details»
Bristol Myers Squibb Is a Must-Own Stock Right Now. Here's Why.
Source from : The Motley Fool on MSN - 12 days ago
This blue chip big pharma stock offers investors a recession-proof business, a rising top line, and a solid dividend.See details»
Bristol-Myers Squibb, Cash, Cheniere Energy And This Tech Company Are CNBC's Final Trades
Source from : Benzinga.com on MSN - 1 days ago
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said Bristol-Myers Squibb Co (NYSE: BMY) has a “good dividend yield” and is a &l ...See details»
Why Bristol Myers Squibb Stock Bounced Higher Today
Source from : Nasdaq - 2 days ago
Shares of Bristol Myers Squibb were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week. The big drugmaker didnt reportany ...See details»
Is Bristol-Myers Squibb Company's (NYSE:BMY) ROE Of 20% Impressive?
Source from : Yahoo - 4 days ago
To keep the lesson grounded in practicality, we'll use ROE to better understand Bristol-Myers Squibb Company (NYSE:BMY). Return on equity or ROE is a key measure used to assess how efficiently a ...See details»
BMY Bristol-Myers Squibb Company
Source from : Seeking Alpha - 3 days ago
**NM signifies a non meaningful value. A dash signifies the data is not available.See details»
Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock
Source from : Benzinga.com on MSN - 1 days ago
The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades.See details»
Berenberg downgrades Bristol-Myers Squibb, says upside is running out
Source from : CNBC - 10 days ago
Bristol-Myers Squibb shares are running out of room to run after surging nearly 14% year to date, Berenberg said. The group on Tuesday downgraded shares of the pharmaceutical company to hold from ...See details»
Bristol Myers Squibb Shakes Up Key Biotech Battleground
Source from : MSN - 10 days ago
Bristol Myers Squibb (BMY) - Get Bristol-Myers Squibb Company Report certainly did. The $150 billion drug developer enjoyed a 6% pop after announcing FDA approval for one of its closely-watched ...See details»
Is Most-Watched Stock Bristol Myers Squibb Company (BMY) Worth Betting on Now?
Source from : AOL - 11 days ago
Bristol Myers Squibb (BMY) is one of the stocks most watched ... Over the past month, shares of this biopharmaceutical company have returned -2.9%, compared to the Zacks S&P 500 composite's ...See details»